Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chroni Malignancies Working Party of EBMT.

Fiche publication

Date publication

mai 2018

Journal

British journal of haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse

Tous les auteurs :
McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29808926

Résumé

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.